[
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
    "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
    "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743108470,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
      "id": 133501439,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
      "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c"
    }
  },
  {
    "ts": null,
    "headline": "VIG: Index Rebalance Adds Eli Lilly To Bolster Dividend Growth In 2025",
    "summary": "VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, and DGRW ETFs.",
    "url": "https://finnhub.io/api/news?id=e51b13f6428a2a7cd526321e069d59dbfb99688748f82c2b210d4b938684310b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743107997,
      "headline": "VIG: Index Rebalance Adds Eli Lilly To Bolster Dividend Growth In 2025",
      "id": 133501471,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "VIG's recent rebalancing impacts its holdings, yield, and dividend growth streak. Read here for a comparison with SPY, DGRO, and DGRW ETFs.",
      "url": "https://finnhub.io/api/news?id=e51b13f6428a2a7cd526321e069d59dbfb99688748f82c2b210d4b938684310b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): Among Dividend Zombies to Invest in",
    "summary": "We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to invest in. The broader market has posted consecutive annual gains of 25%, largely fueled by growth stocks and companies capitalizing […]",
    "url": "https://finnhub.io/api/news?id=e239504768bcee0a66f6617d723f5a8906e58a4b90f6f846fa0dcb0664f47945",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743105017,
      "headline": "Eli Lilly and Company (LLY): Among Dividend Zombies to Invest in",
      "id": 133485477,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to invest in. The broader market has posted consecutive annual gains of 25%, largely fueled by growth stocks and companies capitalizing […]",
      "url": "https://finnhub.io/api/news?id=e239504768bcee0a66f6617d723f5a8906e58a4b90f6f846fa0dcb0664f47945"
    }
  },
  {
    "ts": null,
    "headline": "Novo shares on track for biggest monthly fall since 2002, investor worries grow",
    "summary": "LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly.  Novo came under pressure last year to prove it could keep its advantage in the lucrative obesity market after U.S. rival Lilly launched its own injection Zepbound, which led in clinical trials to greater weight loss than Wegovy.  That has not happened, say investors and analysts observing rapidly worsening market sentiment toward Novo, despite the fact that Wegovy sales more than doubled in the fourth quarter of last year.",
    "url": "https://finnhub.io/api/news?id=b57aa6a99b264d7b48fccf7f96f99f9b99c44aa4ea44b8bd35d3f90706a4065e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743096558,
      "headline": "Novo shares on track for biggest monthly fall since 2002, investor worries grow",
      "id": 133484807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly.  Novo came under pressure last year to prove it could keep its advantage in the lucrative obesity market after U.S. rival Lilly launched its own injection Zepbound, which led in clinical trials to greater weight loss than Wegovy.  That has not happened, say investors and analysts observing rapidly worsening market sentiment toward Novo, despite the fact that Wegovy sales more than doubled in the fourth quarter of last year.",
      "url": "https://finnhub.io/api/news?id=b57aa6a99b264d7b48fccf7f96f99f9b99c44aa4ea44b8bd35d3f90706a4065e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Expands Digital Platform For Alzheimer's Care As Shares Stay Flat",
    "summary": "Eli Lilly (NYSE:LLY) announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with healthcare providers for Alzheimer's patients—providing a targeted solution for timely diagnosis amid highlighted capacity issues. This aligns with a broader push in addressing Alzheimer's care and may be a factor behind Eli Lilly's 4% price rise over the last quarter. Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's...",
    "url": "https://finnhub.io/api/news?id=974b0a42f74b5eee837f5fab81ac0121f8ccd98df9aa4b184bbbabc3ab2efae5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743096436,
      "headline": "Eli Lilly (NYSE:LLY) Expands Digital Platform For Alzheimer's Care As Shares Stay Flat",
      "id": 133484808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with healthcare providers for Alzheimer's patients—providing a targeted solution for timely diagnosis amid highlighted capacity issues. This aligns with a broader push in addressing Alzheimer's care and may be a factor behind Eli Lilly's 4% price rise over the last quarter. Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's...",
      "url": "https://finnhub.io/api/news?id=974b0a42f74b5eee837f5fab81ac0121f8ccd98df9aa4b184bbbabc3ab2efae5"
    }
  },
  {
    "ts": null,
    "headline": "Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025",
    "summary": "Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.",
    "url": "https://finnhub.io/api/news?id=f05027003a8620411e6294f9c2aa46233193b0a97ff71d5202f4a92596f08d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743081300,
      "headline": "Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025",
      "id": 133471672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.",
      "url": "https://finnhub.io/api/news?id=f05027003a8620411e6294f9c2aa46233193b0a97ff71d5202f4a92596f08d51"
    }
  },
  {
    "ts": null,
    "headline": "LillyDirect platform expands to facilitate access to Alzheimer's disease care",
    "summary": "Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease, the majority of whom have not been formally diagnosed.1",
    "url": "https://finnhub.io/api/news?id=bd6ac8d29333fba8209daa9339ceee494d05bba31568da1b9d8921068b2ab83e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743080400,
      "headline": "LillyDirect platform expands to facilitate access to Alzheimer's disease care",
      "id": 133471674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease, the majority of whom have not been formally diagnosed.1",
      "url": "https://finnhub.io/api/news?id=bd6ac8d29333fba8209daa9339ceee494d05bba31568da1b9d8921068b2ab83e"
    }
  },
  {
    "ts": null,
    "headline": "Organovo Provides Business Update",
    "summary": "SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update. With the closing of the sale of its FXR Program to Lilly (NYSE:LLY), Organovo has received upfront payments and anticipates future milestone payments. When combined with funding from previously reported warrant exercises and ad",
    "url": "https://finnhub.io/api/news?id=f5161b20293a2f94225de3e37f788758e32afd8373f20773783b66495416a576",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743077100,
      "headline": "Organovo Provides Business Update",
      "id": 133467991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update. With the closing of the sale of its FXR Program to Lilly (NYSE:LLY), Organovo has received upfront payments and anticipates future milestone payments. When combined with funding from previously reported warrant exercises and ad",
      "url": "https://finnhub.io/api/news?id=f5161b20293a2f94225de3e37f788758e32afd8373f20773783b66495416a576"
    }
  },
  {
    "ts": null,
    "headline": "Investors in Eli Lilly (NYSE:LLY) have seen massive returns of 544% over the past five years",
    "summary": "Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...",
    "url": "https://finnhub.io/api/news?id=98ae0d0e5d0e4ae878167a98d2943dd2e34a118e006830b905d9fe430ae46fd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743073255,
      "headline": "Investors in Eli Lilly (NYSE:LLY) have seen massive returns of 544% over the past five years",
      "id": 133467993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...",
      "url": "https://finnhub.io/api/news?id=98ae0d0e5d0e4ae878167a98d2943dd2e34a118e006830b905d9fe430ae46fd0"
    }
  },
  {
    "ts": null,
    "headline": "Columbia Select Large Cap Growth Fund Q4 2024 Commentary",
    "summary": "For Q4 2024,  Columbia Select Large Cap Growth Fund Institutional Class shares returned 4.16%. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f8efebf14f123d2251ca8a8d97d693d394238a78522ed0dd8e6451be3b82142c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743072600,
      "headline": "Columbia Select Large Cap Growth Fund Q4 2024 Commentary",
      "id": 133475602,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/847843352/image_847843352.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q4 2024,  Columbia Select Large Cap Growth Fund Institutional Class shares returned 4.16%. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=f8efebf14f123d2251ca8a8d97d693d394238a78522ed0dd8e6451be3b82142c"
    }
  }
]